On August 7, 2025, before the market opened, the company issued a press release entitled “Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps.” The release stated that Tandem Diabetes had “announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.”
On this news, Tandem Diabetes’ stock fell $2.87 per share, or 19.9%, to close at $11.52 per shareon August 7, 2025.
